First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC / SCLC, Extensive Stage / Chemotherapy · Phase 2 Trial

Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

ClinicalTrials.gov · August 17, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a planned Phase 2 trial comparing concurrent versus sequential radiotherapy with adebelizumab and chemotherapy in untreated extensive-stage small cell lung cancer. No results are reported in this registry record; the study is actively recruiting.

What was studied

Phase 2, Interventional, Single Group, Open label, Treatment purpose. SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy; age from 18 Years. Intervention: experimental group. Compared with: Adebelizumab combined with chemotherapy administered sequentially with thoracic radiotherapy. n = 60. 1 site: China.

Key findings

Safety

This is a registry record with no results reported; efficacy and safety data are not yet available.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a Phase 2 interventional trial still recruiting with no results reported; it is early-stage work designed to evaluate a treatment strategy before confirmatory testing.

Study design

As stated by the source record.

MethodsPrimary outcome measure: PFS (assessed at From enrollment to the end of treatment at 1 year)

DesignPhase 2, Interventional, Single Group, Open label, Treatment purpose

PopulationSCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy; age from 18 Years

Sample size60

Interventionexperimental group

ComparatorAdebelizumab combined with chemotherapy administered sequentially with thoracic radiotherapy

Setting1 site: China

Reported figures

Quoted from the source exactly as published.

Planned enrollment60

PhasePhase 2

Primary outcome measurePFS from enrollment to end of treatment at 1 year

Study statusRECRUITING

Caveats

This is a registry record with no results reported; efficacy and safety data are not yet available.
Planned primary endpoint is PFS at 1 year; timing of final analysis and follow-up duration beyond 1 year are not specified.
No information on randomization method, blinding, or statistical analysis plan is provided.
The comparison is between concurrent and sequential radiotherapy schedules, not against a control arm without radiotherapy; comparative effect size cannot be assessed from this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Phase 2 interventional study with two treatment arms; design appropriate for early efficacy evaluation.

Directness

strong

Directly addresses first-line treatment of extensive-stage SCLC with relevant clinical population.

Consistency

insufficient

Registry record only; no comparative data or consistency assessment possible without results.

Risk of bias

insufficient

No methodological detail on blinding, allocation concealment, or analysis plan provided in registry.

Sample adequacy

limited

Estimated enrollment of 60 participants is modest for a Phase 2 comparative trial.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT06768307). This is a study registration, not published results. Lead sponsor: Peking University Cancer Hospital & Institute. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy. Interventions: DRUG: First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC. Primary outcome measures: PFS , From enrollment to the end of treatment at 1 year. Brief summary: Immunotherapy combined with chemotherapy has emerged as the standard of care for patients with extensive-stage small cell lung cancer (ES-SCLC). The incorporation of thoracic radiotherapy can enhance treatment efficacy. Currently, the main types of research investigating immunotherapy combined with thoracic radiotherapy for untreated ES-SCLC are concurrent radiotherapy and sequential radiotherapy. The aim of this study is to evaluate the efficacy of adebelizumab in combination with chemotherapy, when administered concurrently with radiotherapy versus sequentially with radiotherapy, as a first-line treatment for ES-SCLC.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLCSCLC, Extensive StagePeking University Cancer Hospital & InstituteChemotherapyImmunotherapyNCT06768307